Selected article for: "AZM combination and large scale"
Author: Jennifer C.E Lane; James Weaver; Kristin Kostka; Talita Duarte-Salles; Maria Tereza F. Abrahao; Heba Alghoul; Osaid Alser; Thamir M Alshammari; Patricia Biedermann; Edward Burn; Paula Casajust; Mitch Conover; Aedin C. Culhane; Alexander Davydov; Scott L. DuVall; Dmitry Dymshyts; Sergio Fernández Bertolín; Kristina Fišter; Jill Hardin; Laura Hester; George Hripcsak; Seamus Kent; Sajan Khosla; Spyros Kolovos; Christophe G. Lambert; Johan ver der Lei; Ajit A. Londhe; Kristine E. Lynch; Rupa Makadia; Andrea V. Margulis; Michael E. Matheny; Paras Mehta; Daniel R. Morales; Henry Morgan-Stewart; Mees Mosseveld; Danielle Newby; Fredrik Nyberg; Anna Ostropolets; Rae Woong Park; Albert Prats-Uribe; Gowtham A. Rao; Christian Reich; Jenna Reps; Peter Rijnbeek; Selva Muthu Kumaran Sathappan; Martijn Schuemie; Sarah Seager; Anthony Sena; Azza Shoaibi; Matthew Spotnitz; Marc A. Suchard; Joel Swerdel; Carmen Olga Torre; David Vizcaya; Haini Wen; Marcel de Wilde; Seng Chan You; Lin Zhang; Oleg Zhuk; Patrick Ryan; Daniel Prieto-Alhambra
Title: Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
  • Document date: 2020_4_10
    • ID: 2hbcbvt6_3
    Snippet: In preparation for our study, we systematically searched the literature (PubMed, Embase), clinical trial registries (Clinicaltrials.gov, ICTRP and Chinese Clinical Trial Registry) and preprint servers (bioRxiv and medRxiv) from inception until 27/03/2020 (Supplementary appendix section 11) . No contemporary large-scale evidence was found to identify the real-world comparative safety of HCQ compared to other first line DMARDs, especially in combin.....
    Document: In preparation for our study, we systematically searched the literature (PubMed, Embase), clinical trial registries (Clinicaltrials.gov, ICTRP and Chinese Clinical Trial Registry) and preprint servers (bioRxiv and medRxiv) from inception until 27/03/2020 (Supplementary appendix section 11) . No contemporary large-scale evidence was found to identify the real-world comparative safety of HCQ compared to other first line DMARDs, especially in combination with macrolide antibiotics such as AZM that are being considered for use in treating COVID-19.

    Search related documents:
    Co phrase search for related documents
    • clinical trial registry and comparative safety: 1, 2
    • clinical trial registry and Embase PubMed literature: 1, 2, 3, 4
    • clinical trial registry and large scale: 1, 2, 3, 4
    • clinical trial registry and real world: 1, 2, 3, 4, 5, 6, 7, 8
    • clinical trial registry and trial registry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • comparative safety and large scale: 1, 2, 3
    • comparative safety and large scale evidence: 1
    • comparative safety and real world: 1, 2, 3
    • comparative safety and trial registry: 1, 2, 3
    • Embase PubMed literature and large scale: 1, 2, 3, 4, 5
    • Embase PubMed literature and real world: 1, 2, 3, 4, 5
    • Embase PubMed literature and study preparation: 1
    • Embase PubMed literature and trial registry: 1, 2, 3, 4
    • large scale and real world: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • large scale and study preparation: 1, 2, 3
    • large scale and trial registry: 1, 2, 3, 4, 5
    • large scale evidence and real world: 1, 2
    • real world and trial registry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10